Clinical Psychiatry News - Lilly warned on Cymbalta
A promotional brochure mailed to physicians on Cymbalta (duloxetine) delayed-release capsules overstates the drug’s efficacy and “omits some of the most serious and important risk information associated with its use,” said the Food and Drug Administration in a late September warning letter sent to the drug’s maker, Eli Lilly & Co.
Related Results
Cymbalta contractCymbalta approvalCymbalta launch expectedCymbalta for GAD, Humira for Crohn’sCymbalta Approved for Fibromyalgia
The agency questioned the references used to support the efficacy claims, and also said that even though the brochure included information from the boxed warning, it did not include contraindications in uncontrolled narrow-angle glaucoma and with monoamine oxidase inhibitors.
COPYRIGHT 2007 International Medical News Group
COPYRIGHT 2008 Gale, Cengage Learning
